Amgen Inc. stock: Pipeline pivot eyes $37-38B sales amid biosimilar risks

Amgen is targeting $37-38.4 billion in 2026 sales by shifting focus to next-gen drugs like obesity candidate MariTide, countering biosimilar erosion on legacy products. This strategic move matters for you as a global investor seeking resilient biotech plays with dividend strength. ISIN: US0311621009

Amgen Inc. is steering its future with a bold pipeline pivot, aiming for $37-38.4 billion in sales by 2026 as biosimilars chip away at its blockbuster drugs. You’re watching this stock because it blends steady dividends with high-stakes innovation in obesity and oncology, key areas for long-term growth in biotech. Whether you're investing from the U.S., Europe, or beyond, understanding Amgen's transition helps you gauge if it's a buy now amid market volatility.

As of: 06.04.2026

By Elena Harper, Senior Biotech Equity Editor: Amgen stands at the crossroads of legacy revenue defense and next-generation breakthroughs in a competitive pharma landscape.

Amgen's Core Business: Human Therapeutics at Scale

Amgen builds its empire on human therapeutics, targeting unmet needs in oncology, cardiovascular disease, inflammation, bone health, and now obesity. You know the names: drugs like Prolia and XGEVA have driven billions, but biosimilar competition is forcing a rethink. This isn't just maintenance mode—it's about evolving a portfolio that generated $36.8 billion last year into something sustainable for decades.

The company's rare disease unit and immunology push add layers of diversification. For you as an investor, this means Amgen isn't betting everything on one horse. Instead, it's balancing mature cash cows with pipeline bets that could redefine its growth trajectory. Global demand for these therapies keeps the revenue engine humming, even as patents expire.

Think about your portfolio: Amgen's scale gives it firepower to weather storms that sink smaller biotechs. With operations spanning the U.S. and international markets, it's positioned to capture value wherever patients need advanced treatments. That's the foundation—reliable, but now demanding strategic upgrades.

Strategic Shift: MariTide and Beyond for 2026 Growth

At the heart of Amgen's pivot is MariTide, a monthly-dose obesity drug challenging weekly giants like those from Eli Lilly and Novo Nordisk. This isn't hype—it's a calculated move to grab share in a market exploding with demand for effective weight management. You should buy now if you believe in Amgen's execution here, as success could add billions to the top line.

Legacy products face headwinds, with Prolia and XGEVA expected to lose ground to biosimilars. Amgen counters by ramping volumes in cardio and oncology, plus new patient starts in immunology. The 2026 sales target of $37-38.4 billion signals confidence, with operating margins around 43% underscoring efficiency.

For global investors, this shift resonates because obesity therapies transcend borders—U.S. approvals often pave the way for Europe and Asia. Watch clinical readouts closely; they're your signal for upside. Amgen's not reinventing the wheel but sharpening it for the long haul.

Financial Backbone: Dividends and Margins That Matter to You

Amgen rewards patience with a robust dividend, increased for years running, yielding competitively in biotech. You get income while waiting for pipeline wins, a rare combo in this sector. Pair that with projected margins holding steady, and it's a defensive play amid volatility.

Recent trading shows resilience—around levels that blend stability with growth potential. For U.S. investors, it's Nasdaq-listed (NASDAQ: AMGN) in USD; Europeans can access via ADRs or local exchanges. This universality makes it a staple for diversified portfolios worldwide.

What matters most right now? That 2026 target isn't pie-in-the-sky—it's backed by volume growth plans offsetting $36.8 billion from last year. If biosimilars hit harder than expected, margins provide a buffer. You're not just buying a stock; you're investing in a machine tuned for consistency.

Analyst Views: What Banks See in Amgen's Trajectory

Reputable analysts track Amgen closely, focusing on its pipeline pivot and biosimilar resilience. While specific recent ratings vary, the consensus leans toward holding steady bets on innovation like MariTide amid revenue transition pressures. Banks highlight the 2026 sales guidance as a key metric, with oncology and obesity as bright spots.

You'll find coverage emphasizing Amgen's dividend strength and margin discipline as reasons to stay engaged, even if near-term legacy declines loom. Major houses view the strategic shift positively for long-term positioning, though execution risks temper enthusiasm. This balanced take suits investors like you seeking verified perspectives before acting.

Overall, the analyst picture underscores why Amgen draws attention: it's not flashy, but its evolution aligns with global health trends. Check primary sources for the freshest notes—your decision hinges on how their models weigh MariTide's potential against competitive erosion.

Risks and Open Questions: Biosimilars and Execution Hurdles

No biotech stock skips risks, and Amgen's no exception—biosimilars for Humira and others signal rapid market shifts. The Humira biosimilar space alone could balloon to nearly $10 billion by 2033, squeezing originators like Amgen's peers and indirectly pressuring the sector. You need to watch how deeply this erodes Amgen's ortho and inflammation revenues.

Pipeline risks loom large: MariTide's monthly dosing sounds great, but trial delays or efficacy shortfalls could derail 2026 goals. Regulatory hurdles in Europe or Asia add uncertainty for your global portfolio. Plus, broader tariff talks on drugs highlight policy wildcards that could hike costs.

What should you watch next? Q1 results on April 30, 2026, and the shareholder meeting May 19—early indicators of pivot success. If volumes grow as planned, it's a buy signal; stalls mean caution. Balance these against Amgen's cash pile and R&D muscle, giving it room to maneuver.

Why Amgen Matters to You as a Global Investor

Amgen fits your strategy if you prioritize biotech with income and upside. U.S. investors get direct Nasdaq exposure; Europeans via exchanges like Xetra; globals through ETFs. Its focus on universal needs like cancer and obesity makes it recession-resistant.

Relevance now? The pipeline shift positions Amgen ahead of pure-play obesity stocks, blending defense with offense. Should you buy? If you trust the 2026 outlook and dividend, yes—otherwise, wait for Q1 proof. This stock rewards those who dig into the details.

Track catalysts like MariTide data and biosimilar impacts. Your edge comes from separating noise from validated strategy—Amgen delivers that clarity. Build wealth by aligning with companies navigating change this deliberately.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.